
Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by $9 billion.
Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023.